191 related articles for article (PubMed ID: 21868233)
1. Relapse of primary central nervous system lymphoma 13 years after high-dose methotrexate-based polychemotherapy.
Steinbeck JA; Stuplich M; Blasius E; Pels H; Glas M; Schlegel U; Herrlinger U
J Clin Neurosci; 2011 Nov; 18(11):1554-5. PubMed ID: 21868233
[TBL] [Abstract][Full Text] [Related]
2. Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma.
Kim SJ; Oh SY; Kim JS; Kim H; Lee GW; Won JH; Shin HJ; Yang DH; Choi CW; Park J; Kim WS; Suh C
Ann Hematol; 2011 May; 90(5):539-46. PubMed ID: 20960190
[TBL] [Abstract][Full Text] [Related]
3. Long-term remission of primary central nervous system lymphoma by intensified methotrexate chemotherapy.
Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T; Fukushima T
J Neurooncol; 2003 May; 63(1):87-95. PubMed ID: 12814260
[TBL] [Abstract][Full Text] [Related]
4. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate.
Plotkin SR; Betensky RA; Hochberg FH; Grossman SA; Lesser GJ; Nabors LB; Chon B; Batchelor TT
Clin Cancer Res; 2004 Sep; 10(17):5643-6. PubMed ID: 15355887
[TBL] [Abstract][Full Text] [Related]
5. [Primary central nervous system lymphoma--a report of 32 cases with literature review].
Yi JQ; Lin TY; He YJ; Huang HQ; Xia ZJ; Xia YF; Xu RH; Guo Y; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):476-80. PubMed ID: 16613684
[TBL] [Abstract][Full Text] [Related]
6. [High-dose methotrexate followed by whole-brain irradiation for primary central nervous system lymphoma patients--a retrospective study in a single institute].
Usui N; Dobashi N; Yano S; Yahagi Y; Takei Y; Otsubo H; Takahara S; Yamaguchi Y; Saito T; Minami J; Kamiyama Y; Morikawa N; Machishima T; Osawa H; Aiba K
Gan To Kagaku Ryoho; 2010 Jul; 37(7):1277-82. PubMed ID: 20647709
[TBL] [Abstract][Full Text] [Related]
7. Primary central nervous system lymphoma: monocenter, long-term, intent-to-treat analysis.
Kiewe P; Fischer L; Martus P; Thiel E; Korfel A
Cancer; 2008 Apr; 112(8):1812-20. PubMed ID: 18318432
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma.
Green MR; Chowdhary S; Lombardi KM; Chalmers LM; Chamberlain M
Expert Rev Neurother; 2006 May; 6(5):635-52. PubMed ID: 16734512
[TBL] [Abstract][Full Text] [Related]
9. Treatment of primary CNS lymphoma with high-dose methotrexate in immunocompetent pediatric patients.
Shah AC; Kelly DR; Nabors LB; Oakes WJ; Hilliard LM; Reddy AT
Pediatr Blood Cancer; 2010 Dec; 55(6):1227-30. PubMed ID: 20882580
[TBL] [Abstract][Full Text] [Related]
10. Combined-modality therapy for primary central nervous system lymphoma: long-term data from a Phase II multicenter study (Trans-Tasman Radiation Oncology Group).
O'Brien PC; Roos DE; Pratt G; Liew KH; Barton MB; Poulsen MG; Olver IN; Trotter GE;
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):408-13. PubMed ID: 16198065
[TBL] [Abstract][Full Text] [Related]
11. Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas.
Ferreri AJ; Dell'Oro S; Capello D; Ponzoni M; Iuzzolino P; Rossi D; Pasini F; Ambrosetti A; Orvieto E; Ferrarese F; Arrigoni G; Foppoli M; Reni M; Gaidano G
Br J Haematol; 2004 Sep; 126(5):657-64. PubMed ID: 15327516
[TBL] [Abstract][Full Text] [Related]
12. High-dose methotrexate is beneficial in parenchymal brain masses of uncertain origin suspicious for primary CNS lymphoma.
Kiewe P; Loddenkemper C; Anagnostopoulos I; Reinwald M; Thiel E; Korfel A
Neuro Oncol; 2007 Apr; 9(2):96-102. PubMed ID: 17301290
[TBL] [Abstract][Full Text] [Related]
13. Comparison of 2-methoxyestradiol and methotrexate effects on non-Hodgkin's B-cell lymphoma.
Park J; Franco RS; Augsburger JJ; Banerjee RK
Curr Eye Res; 2007; 32(7-8):659-67. PubMed ID: 17852190
[TBL] [Abstract][Full Text] [Related]
14. Primary central nervous system lymphoma: an unusual presentation.
Heckmann JM; O'Ryan S; Candy S
S Afr Med J; 2008 Nov; 98(11):851-2. PubMed ID: 19177889
[No Abstract] [Full Text] [Related]
15. The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients.
Kasenda B; Rehberg M; Thürmann P; Franzem M; Veelken H; Fritsch K; Schorb E; Finke J; Lebiedz D; Illerhaus G
Ann Hematol; 2012 Aug; 91(8):1257-64. PubMed ID: 22456893
[TBL] [Abstract][Full Text] [Related]
16. Primary central nervous system lymphomas: salvage treatment after failure to high-dose methotrexate.
Reni M; Mazza E; Foppoli M; Ferreri AJ
Cancer Lett; 2007 Dec; 258(2):165-70. PubMed ID: 17993246
[TBL] [Abstract][Full Text] [Related]
17. High-dose methotrexate for intraocular lymphoma.
Batchelor TT; Kolak G; Ciordia R; Foster CS; Henson JW
Clin Cancer Res; 2003 Feb; 9(2):711-5. PubMed ID: 12576439
[TBL] [Abstract][Full Text] [Related]
18. Primary central nervous system lymphoma.
Mohile NA; Abrey LE
Semin Radiat Oncol; 2007 Jul; 17(3):223-9. PubMed ID: 17591569
[TBL] [Abstract][Full Text] [Related]
19. Severe complications after intrathecal methotrexate (MTX) for treatment of primary central nervous system lymphoma (PCNSL).
Weigel R; Senn P; Weis J; Krauss JK
Clin Neurol Neurosurg; 2004 Mar; 106(2):82-7. PubMed ID: 15003295
[TBL] [Abstract][Full Text] [Related]
20. Primary CNS lymphoma: a clinician's guide.
Schäfer N; Glas M; Herrlinger U
Expert Rev Neurother; 2012 Oct; 12(10):1197-206. PubMed ID: 23082736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
